2023 World Conference on Lung Cancer (Posters)-P2.09. Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis

P2.09. Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis - PDF(Abstract)

Back to course

Pdf Summary

The study presented at the WCLC 2023 conference focused on comparing the efficacy and safety of Lazertinib and Gefitinib in Asian patients with treatment-naïve EGFR-mutated non-small cell lung cancer (NSCLC). Lazertinib is a third-generation tyrosine kinase inhibitor (TKI) that targets mutant EGFR in NSCLC, while sparing wild-type EGFR. Osimertinib, another third-generation EGFR TKI, has shown longer progression-free survival (PFS) but failed to demonstrate an overall survival (OS) benefit in Asian or L858R-mutated subgroups. <br /><br />The LASER301 study compared Lazertinib and Gefitinib in a randomized, double-blind, multinational phase 3 study. The primary endpoint was investigator-assessed PFS, and secondary endpoints included OS, objective response rate (ORR), duration of response (DoR), and safety. A total of 393 patients were enrolled in the study, with 258 of them being of Asian descent.<br /><br />The results showed that Lazertinib demonstrated significantly longer median PFS compared to Gefitinib (20.6 vs 9.7 months), with a hazard ratio of 0.46. This PFS benefit was consistent across various subgroups, including those with Ex19del mutations, L858R mutations, and CNS metastases at study entry. The ORR and disease control rate were similar between both treatment groups. Adverse event rates were comparable in Asian patients compared to the overall study population, with paronychia, paraesthesia, and liver enzyme abnormalities being the most common AEs.<br /><br />In conclusion, Lazertinib showed better efficacy than Gefitinib in Asian patients with EGFR-mutated advanced NSCLC, with a tolerable safety profile. These findings suggest that Lazertinib may be a promising treatment option for this patient population.

Asset Subtitle

Thanyanan Reungwetwattana

Meta Tag

Speaker Thanyanan Reungwetwattana

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023

Lazertinib

Gefitinib

Asian patients

EGFR-mutated

NSCLC

PFS

LASER301 study

safety